Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
tocilizumab
tocilizumab
- Restricted Restricted to Outpatient Medical (for Non-COVID19/CRS).
- Restricted COVID-19 Criteria for Use
- Restricted Miscellaneous Programs
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Avtozma | INJECTION, INTRAVENOUS | 20 mg/mL | ||||
| Tyenne | INJECTION, INTRAVENOUS | 20 mg/mL | ||||
| Actemra | INJECTION, SUBCUTANEOUS | 162 mg/0.9 mL | ||||
| Avtozma | INJECTION, SUBCUTANEOUS | 162 mg/0.9 mL | ||||
| Actemra | SOLUTION, INTRAVENOUS | 20 mg/mL | ||||
| Tofidence | SOLUTION, INTRAVENOUS | 20 mg/mL |
Last updated: Jun. 12, 2025
- Black Box Warning: Serious infections risk
Cytokine Release Syndrome (CRS): Tocilizumab inpatient use is restricted to oncology/hematology providers.
COVID-19: Due to the potential role in treatment of COVID-19 in patients with evidence of cytokine release, tocilizumab may be utilized in select patients when prescribed by Infectious Diseases or Pediatric Critical Care following Huntsville Hospital's Criteria for Use. Due to limited supply, availability of this medication is not guaranteed.
Other Indications: Tocilizumab is as restricted to outpatient use.
TOFIDENCE: Therapeutically equivalent to Actemra for treatment of COVID-19 and CRS. The most cost-effective product may be utilized. Tofidence use in other indications is pending further review by P&T.
Avtozma & Tyenne: Therapeutically equivalent to Actemra for treatment of COVID-19 and CRS. The most cost effective product may be utilized.
Actemra medication guide
Reviewed: December 2023 (Tofidence) , May 2025 (Avtozma/Tyenne)
Updated: March 2024 (Inpatient Use, Tofidence)
Tocilizuymab-bavi (Tofidence)
Tocilizumab-bavi (Tofidence) CRS Update
Tocilizumab-anoh (AVTOZMA) Spotlight.pdf
Tocilizumab-aazg (TYENNE) Spotlight.pdf